heart failure
Cardiovascular · 2005–2025
17decisions
7medicines
8carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| eplerenone Chronic heart failure with left ventricular ejection fraction ≤40%, either within 3-14 days following acute myocardial infarction or in symptomatic patients… | Dec 2025 | Recommended | input received |
| empagliflozin Treatment of chronic heart failure in patients who are symptomatic (NYHA classes II, III or IV) with documented left ventricular ejection fraction (LVEF) of… | Mar 2024 | Recommended | none received |
| sacubitril with valsartan Treatment of chronic heart failure (NYHA Class II-IV) with reduced left ventricular ejection fraction in adult patients. This submission specifically requested… | Nov 2024 | Recommended | input received |
| dapagliflozin Treatment of chronic heart failure patients with left ventricular ejection fraction (LVEF) greater than 40% who are receiving standard of care therapy. | Jul 2023 | Recommended | input received Diabetes Australia |
| vericiguat Treatment of symptomatic chronic heart failure (NYHA class II, III or IV) in patients with reduced ejection fraction (LVEF <45%) who are stabilised after a… | Jul 2022 | Recommended with restriction | none received |
| vericiguat Treatment of symptomatic chronic heart failure with reduced ejection fraction (LVEF <45%) in adult patients who are stabilised after a recent decompensation… | Mar 2022 | Not recommended | input received |
| empagliflozin Treatment of chronic heart failure (NYHA classes II, III, or IV) with left ventricular ejection fraction greater than 40%, as an adjunct to standard care. | Dec 2022 | Recommended with restriction | input received Diabetes Australia |
| dapagliflozin Treatment of symptomatic heart failure with reduced ejection fraction (HFrEF) in patients receiving concomitant optimal standard chronic heart failure… | Sep 2021 | Recommended with restriction | input received Diabetes Australia |
| empagliflozin Treatment of chronic heart failure with reduced ejection fraction (HFrEF) with LVEF ≤40%, NYHA class II-IV, in patients receiving standard care including a… | Nov 2021 | Recommended | input received |
| sacubitril with valsartan Treatment of chronic heart failure (NYHA Class II-IV) with reduced left ventricular ejection fraction (≤40%) in patients with previous or current use of ACE… | Jul 2016 | Deferred | input received |
| ivabradine Chronic heart failure in symptomatic patients (NYHA classes II or III) with reduced left ventricular ejection fraction (≤35%) and elevated resting heart rate… | Mar 2015 | Recommended with restriction | no section in document |
| Ivabradine Treatment of symptomatic systolic heart failure in patients in sinus rhythm, with a heart rate of at least 75 bpm, measured after 5 minutes rest, who are… | Jul 2012 | Recommended | no section in document |
| ivabradine Treatment of symptomatic systolic heart failure in patients in sinus rhythm, with a heart rate of at least 75 beats per minute, stabilised on optimal heart… | Jul 2012 | Deferred | no section in document |
| Ivabradine Initial and continuing treatment of symptomatic systolic heart failure in a patient in sinus rhythm, with heart rate at or above 70 bpm stabilised on… | Nov 2011 | Not recommended | unclear |
| nebivolol hydrochloride treatment of stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older (TGA indication) | Nov 2009 | Recommended with restriction | no section in document |
| nebivolol hydrochloride Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II receptor antagonist (if… | Nov 2009 | Recommended with restriction | no section in document |
| eplerenone Prevention of cardiovascular death in combination with standard medical therapy in patients who have evidence of heart failure and left ventricular impairment… | Jul 2005 | Recommended with restriction | no section in document |
Who spoke
Diabetes Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 8 of 11 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.